science
중도 성향
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
STAT News
조회 0
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population. ...
관련 뉴스
관련 뉴스 제보는 로그인 후 가능합니다.